FoxP3 and Bcl-xL cooperatively promote regulatory T cell persistence and prevention of arthritis development

Arthritis Research and Therapy

Volumn 12, Issue 2, 2010, Pages

  Haque, Rizwanul ^a   Lei, Fengyang ^a   Xiong, Xiaofang ^a   Wu, Yuzhang ^b   Song, Jianxun ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL XL; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR FOXP3; BCL2L1 PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; PROTEIN BCL X;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; GENE EXPRESSION; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PICORNAVIRUS; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTHRITIS; C57BL MOUSE; DBA MOUSE; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BCL-X PROTEIN; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; T-LYMPHOCYTES, REGULATORY; TRANSDUCTION, GENETIC;

EID: 77950638392     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2983     Document Type: Article

References (49)

1. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009, 10:689-695. 10.1038/ni.1760, 19536194.
2. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061. 10.1126/science.1079490, 12522256.
3. Wei J, Duramad O, Perng OA, Reiner SL, Liu YJ, Qin FX. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2007, 104:18169-18174. 10.1073/pnas.0703642104, 2084315, 17978190.
4. Samon JB, Champhekar A, Minter LM, Telfer JC, Miele L, Fauq A, Das P, Golde TE, Osborne BA. Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood 2008, 112:1813-1821. 10.1182/blood-2008-03-144980, 2518888, 18550850.
5. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005, 201:1061-1067. 10.1084/jem.20042276, 2213134, 15809351.
6. Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 2009, 10:1178-1184. 10.1038/ni.1791, 19783988.
7. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569. 10.1038/nature06306, 18033300.
8. Kerstan A, Hunig T. Cutting edge: distinct TCR- and CD28-derived signals regulate CD95L, Bcl-xL, and the survival of primary T cells. J Immunol 2004, 172:1341-1345.
9. Verschelde C, Walzer T, Galia P, Biemont MC, Quemeneur L, Revillard JP, Marvel J, Bonnefoy-Berard N. A1/Bfl-1 expression is restricted to TCR engagement in T lymphocytes. Cell Death Differ 2003, 10:1059-1067. 10.1038/sj.cdd.4401265, 12934080.
10. Josefowicz SZ, Wilson CB, Rudensky AY. Cutting edge: TCR stimulation is sufficient for induction of Foxp3 expression in the absence of DNA methyltransferase 1. J Immunol 2009, 182:6648-6652. 10.4049/jimmunol.0803320, 19454658.
11. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005, 115:2904-2913. 10.1172/JCI23961, 1201661, 16167085.
12. Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X, Liu R, Balcarcel RR, Fisher N, Levine BL, Carroll RG, Warner N, Blazar BR, June CH, Riley JL. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008, 181:2855-2868. 2556987, 18684977.
13. Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005, 6:152-162. 10.1038/ni1160, 15640801.
14. Song J, So T, Croft M. Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol 2008, 180:7240-7248. 2410213, 18490723.
15. Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat Immunol 2004, 5:150-158. 10.1038/ni1030, 14730361.
16. Song J, So T, Cheng M, Tang X, Croft M. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005, 22:621-631. 10.1016/j.immuni.2005.03.012, 15894279.
17. Song J, Salek-Ardakani S, So T, Croft M. The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol 2007, 8:64-73. 10.1038/ni1413, 17128276.
18. Zhao B, Song A, Haque R, Lei F, Weiler L, Xiong X, Wu Y, Croft M, Song J. Cooperation between molecular targets of costimulation in promoting T cell persistence and tumor regression. J Immunol 2009, 182:6744-6752. 10.4049/jimmunol.0804387, 19454669, 2748393.
19. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336. 10.1038/ni904, 12612578.
20. van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, Tak PP. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004, 6:R239-249. 10.1186/ar1165, 416442, 15142270.
21. Mullazehi M, Mathsson L, Lampa J, Ronnelid J. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum 2006, 54:1759-1771. 10.1002/art.21892, 16736518.
22. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001, 15:445-455. 10.1016/S1074-7613(01)00191-1, 11567634.
23. Charbonnier LM, Han WG, Quentin J, Huizinga TW, Zwerina J, Toes RE, Jorgensen C, Louis-Plence P. Adoptive transfer of IL-10-secreting CD4(+)CD49b(+) regulatory T cells suppresses ongoing arthritis. J Autoimmun 2009,
24. Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, van Laar JM, de Vries RR, Toes RE. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 2005, 52:2212-2221. 10.1002/art.21195, 15986351.
25. Andersen KG, Butcher T, Betz AG. Specific immunosuppression with inducible Foxp3-transduced polyclonal T cells. PLoS Biol 2008, 6:e276. 10.1371/journal.pbio.0060276, 2581628,2581628, 18998771.
26. Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009, 229:41-66. 10.1111/j.1600-065X.2009.00775.x, 19426214, 2714548.
27. Burmeister Y, Lischke T, Dahler AC, Mages HW, Lam KP, Coyle AJ, Kroczek RA, Hutloff A. ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol 2008, 180:774-782.
28. Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004, 199:1479-1489. 10.1084/jem.20040179, 2211778, 15184501.
29. Mesturini R, Nicola S, Chiocchetti A, Bernardone IS, Castelli L, Bensi T, Ferretti M, Comi C, Dong C, Rojo JM, Yagi J, Dianzani U. ICOS cooperates with CD28, IL-2, and IFN-gamma and modulates activation of human naive CD4+ T cells. Eur J Immunol 2006, 36:2601-2612. 10.1002/eji.200535571, 17013990.
30. Nazarov-Stoica C, Surls J, Bona C, Casares S, Brumeanu TD. CD28 signaling in T regulatory precursors requires p56lck and rafts integrity to stabilize the Foxp3 message. J Immunol 2009, 182:102-110.
31. Guo L, Tian J, Marinova E, Zheng B, Han S. Inhibition of clonal expansion by Foxp3 expression as a mechanism of controlled T-cell responses and autoimmune disease. Eur J Immunol 2010, 40:71-80. 10.1002/eji.200939404, 19877010.
32. Frey O, Petrow PK, Gajda M, Siegmund K, Huehn J, Scheffold A, Hamann A, Radbruch A, Brauer R. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells. Arthritis Res Ther 2005, 7:R291-301. 10.1186/ar1484, 1065322, 15743476.
33. Bosselut R. Retroviral TCR gene transduction: 2A for two. Nat Methods 2006, 3:162-164. 10.1038/nmeth0306-162, 16489331.
34. Holst J, Szymczak-Workman AL, Vignali KM, Burton AR, Workman CJ, Vignali DA. Generation of T-cell receptor retrogenic mice. Nat Protoc 2006, 1:406-417. 10.1038/nprot.2006.61, 17406263.
35. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700. 10.1084/jem.20060468, 2118333, 16818676.
36. Mazzucchelli R, Hixon JA, Spolski R, Chen X, Li WQ, Hall VL, Willette-Brown J, Hurwitz AA, Leonard WJ, Durum SK. Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP. Blood 2008, 112:3283-3292. 10.1182/blood-2008-02-137414, 2569178, 18664628.
37. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 2008, 105:19396-19401. 10.1073/pnas.0806855105, 2614772, 19036923.
38. Savage ND, de Boer T, Walburg KV, Joosten SA, van Meijgaarden K, Geluk A, Ottenhoff TH. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J Immunol 2008, 181:2220-2226.
39. Friedline RH, Brown DS, Nguyen H, Kornfeld H, Lee J, Zhang Y, Appleby M, Der SD, Kang J, Chambers CA. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 2009, 206:421-434. 10.1084/jem.20081811, 2646578, 19188497.
40. Fujio K, Okamoto A, Araki Y, Shoda H, Tahara H, Tsuno NH, Takahashi K, Kitamura T, Yamamoto K. Gene therapy of arthritis with TCR isolated from the inflamed paw. J Immunol 2006, 177:8140-8147.
41. Ohata J, Miura T, Johnson TA, Hori S, Ziegler SF, Kohsaka H. Enhanced efficacy of regulatory T cell transfer against increasing resistance, by elevated Foxp3 expression induced in arthritic murine hosts. Arthritis Rheum 2007, 56:2947-2956. 10.1002/art.22846, 17763426.
42. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 2005, 92:913-920. 10.1038/sj.bjc.6602407, 2361917, 15714205.
43. Toubi E, Kessel A, Mahmudov Z, Hallas K, Rozenbaum M, Rosner I. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann N Y Acad Sci 2005, 1051:506-514. 10.1196/annals.1361.095, 16126991.
44. Chatenoud L, Bach JF. Adaptive human regulatory T cells: myth or reality?. J Clin Invest 2006, 116:2325-2327. 1555660, 16955134.
45. Aswad F, Kawamura H, Dennert G. High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2×7 receptors. J Immunol 2005, 175:3075-3083.
46. Pandiyan P, Lenardo MJ. The control of CD4+CD25+Foxp3+ regulatory T cell survival. Biol Direct 2008, 3:6. 10.1186/1745-6150-3-6, 2270257, 18304352.
47. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007, 8:1353-1362. 10.1038/ni1536, 17982458.
48. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001, 31:1122-1131. 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P, 11298337.
49. Wright GP, Notley CA, Xue SA, Bendle GM, Holler A, Schumacher TN, Ehrenstein MR, Stauss HJ. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci USA 2009, 106:19078-19083. 10.1073/pnas.0907396106, 19884493, 2776462.